|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Typhoid | |||||
| Paratyphoid Fever | |||||
| 2 | Additional conditions recognized in this trial | ||||
| Typhoid Fever | |||||
| 3 | More general conditions related to this trial | ||||
| Bacterial Infections | |||||
| Enterobacteriaceae Infections | |||||
| Gram-Negative Bacterial Infections | |||||
| Salmonella Infections | |||||
| 4 | Interventions listed in this trial | ||||
| Typhoid Vi vaccine | |||||
| Hepatitis A vaccine | |||||
| 5 | Sponsors listed in this trial | ||||
| International Vaccine Institute | |||||
| Aga Khan University | |||||
| The Center for Tropical Diseases, Wellcome trust | |||||
| University of Western Ontario, Canada | |||||
| GlaxoSmithKline | |||||